{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:43:15Z","timestamp":1777304595112,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["AI121400"],"award-info":[{"award-number":["AI121400"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Although recent guidelines have recommended monitoring vancomycin (VAN) area under the curve (AUC)\/minimum inhibitory concentration (MIC) to ensure clinical efficacy and minimize toxicity in methicillin-resistant Staphylococcus aureus (MRSA) for various infections, there are no recommendations regarding complicated skin and soft tissue infections (cSSTIs). We aimed to evaluate the association between VAN AUC and clinical outcomes in MRSA cSSTIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective cohort study of adult patients treated with \u226572 hours of VAN for MRSA cSSTI from 2008 to 2013 at Detroit Medical Center. The primary outcome was timely clinical success (TCS) defined as (1) resolution of signs and symptoms of infection within 72 hours, (2) stabilization and\/or reduction in lesion size, (3) alternative agents not required due to VAN failure or toxicity as elected by the prescribing clinician. Classification and regression tree (CART) analysis was performed to determine the AUC associated with TCS in the cohort. Multivariable logistic regression was used to evaluate the association between VAN-AUC and the primary outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 154 patients were included in this analysis. CART identifed an AUC \u2265435 mg*hr\/L for TCS. Overall, 60.9% of patients experienced TCS; 69.7% in the target-AUC group versus 52.5% in the below-target AUC group, (P = .013). Target-AUC attainment was independently associated with increased odds of TCS (adjusted odds ratio [aOR], 2.208; 95% confidence interval [CI], 1.047\u20134.659).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In adults treated with VAN for MRSA cSSTI, target-AUC attainment was independently associated with improved clinical outcomes and maybe most warranted for patients at high risk of VAN failure or VAN-associated toxicity.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciaa1039","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T19:22:47Z","timestamp":1595445767000},"page":"e4560-e4567","source":"Crossref","is-referenced-by-count":11,"title":["Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant<i>Staphylococcus aureus<\/i>Complicated Skin and Soft Tissue Infections"],"prefix":"10.1093","volume":"73","author":[{"given":"Sara","family":"Alosaimy","sequence":"first","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle P","family":"Murray","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Detroit Medical Center, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan J","family":"Zasowski","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Touro University California College of Pharmacy, Vallejo, California, USA"},{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalhamid M","family":"Lagnf","sequence":"additional","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P","family":"Lodise","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"},{"name":"Albany Medical Center Hospital, Albany, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Rybak","sequence":"additional","affiliation":[{"name":"Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Department of Pharmacy, Detroit Medical Center, Detroit, Michigan, USA"},{"name":"School of Medicine, Wayne State University, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"key":"2021121011170407600_CIT0001","doi-asserted-by":"crossref","article-title":"Therapeutic monitoring of vancomycin: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists","author":"Rybak","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"2021121011170407600_CIT0002","doi-asserted-by":"crossref","first-page":"e01293-17","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011170407600_CIT0003","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2146\/ajhp180034","article-title":"Making the change to area under the curve-based vancomycin dosing","volume":"75","author":"Heil","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"2021121011170407600_CIT0004","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011170407600_CIT0005","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/57.suppl_2.S4","article-title":"Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus","volume":"57 Suppl 2","author":"Moise","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"2021121011170407600_CIT0006","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.clinthera.2013.05.008","article-title":"A stewardship program\u2019s retrospective evaluation of vancomycin AUC24\/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"35","author":"Gawronski","year":"2013","journal-title":"Clin Ther"},{"key":"2021121011170407600_CIT0007","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-019-00278-1","article-title":"A multicenter evaluation of vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections","author":"Jorgensen","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2021121011170407600_CIT0008","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021121011170407600_CIT0009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am J Infect Control"},{"key":"2021121011170407600_CIT0010","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021121011170407600_CIT0011","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011170407600_CIT0012","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021121011170407600_CIT0013","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007691-198905000-00009","article-title":"Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations","volume":"11","author":"Rodvold","year":"1989","journal-title":"Ther Drug Monit"},{"key":"2021121011170407600_CIT0014","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00007691-198907000-00013","article-title":"Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models","volume":"11","author":"Pryka","year":"1989","journal-title":"Ther Drug Monit"},{"key":"2021121011170407600_CIT0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.diagmicrobio.2010.02.026","article-title":"Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"67","author":"Neuner","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021121011170407600_CIT0016","doi-asserted-by":"crossref","first-page":"e02478-16","DOI":"10.1128\/AAC.02478-16","article-title":"Pilot study of a Bayesian approach to estimate vancomycin exposure in obese patients with limited pharmacokinetic sampling","volume":"61","author":"Carreno","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011170407600_CIT0017","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011170407600_CIT0018","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9610(02)01411-3","article-title":"A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid","volume":"185","author":"Wilson","year":"2003","journal-title":"Am J Surg"},{"key":"2021121011170407600_CIT0019","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor\u2019s new clothes: PRospective Observational evaluation of the association between initial VancomycIn exposure and failure rates among aDult hospitalizEd patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021121011170407600_CIT0020","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","article-title":"The whole price of vancomycin: toxicities, troughs, and time","volume":"77","author":"Jeffres","year":"2017","journal-title":"Drugs"},{"key":"2021121011170407600_CIT0021","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011170407600_CIT0022","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijantimicag.2010.10.013","article-title":"Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy","volume":"37","author":"Wong-Beringer","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2021121011170407600_CIT0023","doi-asserted-by":"crossref","first-page":"e01684-17","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011170407600_CIT0024","doi-asserted-by":"crossref","first-page":"e02535-16","DOI":"10.1128\/AAC.02535-16","article-title":"Establishment of an AUC(0\u201324) threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia","volume":"61","author":"Chavada","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121011170407600_CIT0025","doi-asserted-by":"crossref","first-page":"e02042-17","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1039\/36246506\/ciaa1039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e4560\/41607554\/ciaa1039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e4560\/41607554\/ciaa1039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T01:09:07Z","timestamp":1667524147000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e4560\/5876762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,7,27]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1039","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,7,27]]}}}